Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. (Q40213973)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

Pawel Krzysztof Wlodarski

21 December 2019

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

7

Mariusz A Wasik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Mouna El-Salem

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Puthiyaveettil N Raghunath

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Donald Tsai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Eric Hsi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

30 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

published in

Laboratory Investigation

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

29-39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075574%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/labinvest.3700494

21 December 2019

exact match

0 references

cites work

The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Epstein-Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

B cells under influence: transformation of B cells by Epstein–Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

mTOR, translational control and human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Human cancer, PTEN and the PI-3 kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Contraction regulation of Akt in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Ribosomal S6 kinase signaling and the control of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Therapeutic potential of target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

inferred from DOI database lookup

7 January 2021

based on heuristic

Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494

inferred from DOI database lookup

7 January 2021

based on heuristic

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700494